Abbvie Inc. vs Krystal Biotech, Inc.
ABBV vs KRYS — side-by-side comparison from reported financials. ABBV leads 4, KRYS leads 6 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Krystal Biotech, Inc.
KRYS · Healthcare
$331.61+1.32%Strained
| Metric | ABBV | KRYS |
|---|---|---|
| Price | $276.43 | $331.61 |
| Market cap | $488B | $9.82B |
| Revenue (TTM) | $64.4B | $440M |
| Revenue growth | +1.8% | +22.6% |
| Net margin | 9.8% | 54.8% |
| Free cash flow | $18.2B | $258M |
| Net cash (debt) | ($56.2B) | $818M |
| 1-year price return | +19.8% | +75.7% |
| P/E | 77.4 | 40.6 |
| P/E vs own history (cheap-side %) | 23% | 63% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 19% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 7 of 11 |
| Employees | 57,000 | 295 |
Full résumé-style profiles: ABBV CV · KRYS CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.